Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (PFE 2.29%) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual.But does that make the stock a buy, or is there reason to be cautious? Let's dig ...